Ultrasound contrast agentdeveloper Molecular Biosystems this month took another step towardcommercializing a new ultrasound agent. The San Diego-based firmhas filed an investigational new drug (IND) application with theFood and Drug Administration for
Ultrasound contrast agentdeveloper Molecular Biosystems this month took another step towardcommercializing a new ultrasound agent. The San Diego-based firmhas filed an investigational new drug (IND) application with theFood and Drug Administration for Oralex, an oral ultrasound agentfor abdominal imaging.
Oralex is designed to fill the stomach and upper gastrointestinaltract, displacing air and improving visualization of organs suchas the pancreas and gallbladder. MBI estimates that about fourmillion abdominal ultrasound scans are performed each year inthe U.S.
Pending FDA approval of the IND, MBI will sponsor phase-oneclinical trials at two university sites. The primary goals ofthe trials will be to evaluate the safety, preliminary efficacyand dose-ranging effects of Oralex.
MBI has licensed European rights to Oralex to Italian contrastsupplier Bracco of Milan (SCAN 6/30/93). MBI does not have a licensingpartner for the agent outside Europe.
In addition to proceeding with clinical development of Oralex,MBI has cleared up legal interference with competitor ImaRx Pharmaceuticalconcerning the agent. ImaRx, of Tucson, AZ, filed suit againstMBI last year, alleging that MBI misappropriated ImaRx trade secretsto develop Oralex (SCAN 7/14/93). ImaRx is developing SonoRx,an oral gastrointestinal ultrasound agent licensed to Squibb Diagnostics.
In a lawsuit filed in the U.S. District Court of Arizona, ImaRxalleged that MBI violated a non-disclosure agreement by usingproprietary information about ImaRx technology to develop Oralex.
MBI and ImaRx settled the lawsuit and a related patent infringementclaim in May, according to Sherry L. Mesman, CFO and vice presidentof finance for MBI. MBI did not disclose the terms of the settlement.
In other MBI news, the company said that researchers at OschnerMedical Institution in New Orleans reported successful resultsin canine testing with FS069, a new second-generation contrastagent for transpulmonary myocardial perfusion echocardiography.The results were reported at the American Society of Echocardiographymeeting in San Francisco last month.
Stay at the forefront of radiology with the Diagnostic Imaging newsletter, delivering the latest news, clinical insights, and imaging advancements for today’s radiologists.
The Reading Room Podcast: A Closer Look at Remote MRI Safety, Part 2
July 25th 2025In the second of a multi-part podcast episode, Emanuel Kanal, M.D. and Tobias Gilk, MRSO, MRSE, share their perspectives on remote MRI safety protocols for ensuring screening accuracy and adherence to conditional implant guidelines as well as a rapid and effective response to adverse events.
The Reading Room Podcast: Current and Emerging Insights on Abbreviated Breast MRI, Part 2
July 23rd 2025In the second part of a multi-part podcast episode, Stamatia Destounis, MD, Emily Conant, MD and Habib Rahbar, MD, discuss key sequences for abbreviated breast MRI and how it stacks up to other breast cancer screening modalities.
Chest CT for Post-COVID-19 Abnormalities: Nine Takeaways from a Multi-Society Consensus Statement
July 22nd 2025Developed by 21 thoracic radiologists, the new international consensus statement addresses appropriate indications, scan acquisition and keys to reporting for the use of chest CT imaging in evaluating for residual lung abnormalities from COVID-19.